ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Study Provides Clues to Undefined, Systemic, Autoinflammatory Diseases

Kurt Ullman  |  September 1, 2020

A study from October 2019 describes the clinical characteristics of pediatric patients with undefined systemic autoinflammatory diseases. Researchers conducted a genetic analysis and outlined specific variants. They found patients with pericarditis and intellectual impairment may have distinct clinical phenotypes, which may lead to improved diagnostic and treatment options.

Filed under:ConditionsOther Rheumatic ConditionsPediatric Conditions Tagged with:geneticPediatricsystemic autoinflammatory diseases

Pharmacists Not Required to Substitute Generics for Brand-Name Drugs in Most U.S. States

Lisa Rapaport  |  September 1, 2020

(Reuters Health)—Only 19 U.S. states mandate that pharmacists fill prescriptions for brand-name small molecule drugs with generics when available, with the 31 remaining states allowing but not requiring these substitutions, a new study finds. Researchers examined laws on the books as of September 2019 pertaining to generic substitution of small molecule drugs, as well as…

Filed under:Drug Updates

After COVID-19-Associated MIS-C, Immune Changes Resolve

Marilynn Larkin  |  September 1, 2020

NEW YORK (Reuters Health)—A new study of multisystem inflammatory syndrome in children (MIS-C) shows that the immune system is profoundly altered during acute illness, but gradually returns back to normal. MIS-C is distinct from both COVID-19 and Kawasaki disease, but is associated with previous SARS-CoV-2 infection, the immunological profiling study reveals. Dr. Manu Shankar-Hari, an…

Filed under:ConditionsOther Rheumatic ConditionsPediatric Conditions Tagged with:ChildrenCOVID-19Multisystem Inflammatory Syndrome in Children (MIS-C)

Biologics May Prevent Cardiovascular Events in RA Patients

Arthritis & Rheumatology  |  August 26, 2020

RA patients experience a higher rate of cardiovascular disease (CVD) events than controls. In a new study, Karpouzas et al. determined that current biologic disease-modifying anti-rheumatic drug use is associated with reduced long-term CVD risk, protective calcification of noncalcified lesions and a lower likelihood of new plaque formation in patients with early atherosclerosis.

Filed under:Biologics/DMARDsConditionsResearch RheumRheumatoid Arthritis Tagged with:Arthritis & Rheumatologybiologic DMARDsCardiovascular diseaseResearchRheumatoid Arthritis (RA)

Dendritic Cells as Therapeutics: The New Frontier

Jason Liebowitz, MD, FACR  |  August 26, 2020

Cancer treatments, organ transplants and rheumatologic diseases—dendritic cells are being used throughout medicine to create innovative treatments, according to presenters of a virtual session during the European e-Congress of Rheumatology.

Filed under:Uncategorized Tagged with:dendritic cellsEULARtherapeutics

Advocacy 101 Teaches Legislative, Advocacy Basics

Vanessa Caceres  |  August 21, 2020

Bharat Kumar, MD, Advocacy 101 coordinator and Government Affairs Committee member, describes the virtual program designed to educate and empower rheumatology fellows in training, program directors and ARP members to advocate for issues that affect rheumatology practices and patients in advance of the Advocates for Arthritis that will take place virtually in September.

Filed under:Education & TrainingLegislation & Advocacy Tagged with:Advocacy 101Advocates for Arthritis

Rheum After 5: Dr. Eric Matteson Writes Rheumatic Disease History

Carol Patton  |  August 12, 2020

Over the past 20 years, Eric L. Matteson, MD, MPH, emeritus chair, Division of Rheumatology, and emeritus professor of medicine at the Mayo Clinic College of Medicine and Science, Rochester, Minn., as well as a past president of the Rheumatology Research Foundation, has authored or co-authored six books about the history of rheumatic disease and…

Filed under:AudioProfilesRheum After 5 Tagged with:Dr. Eric Matteson

How to Create a Safe Practice & Prep for a COVID-19 Resurgence

Steven M. Harris, Esq.  |  August 12, 2020

For many months, the healthcare world has been significantly affected by the swift and per­vasive effects of SARS-CoV-2, which causes COVID-19. The virus has severely affected the delivery of patient care by all providers, including those in hospitals and emergency care settings, who grappled with the response to massive influxes of COVID-19 patients, and those…

Filed under:Legal UpdatesPractice Support Tagged with:COVID-19personal protective equipment (PPE)Safety

Figure 1A–C: Arrows denote hemophagocytic histiocytes.

Case Report: Too Many Activated Immune Cells in a 9-Month-Old Boy

Jeffrey Lo, MD  |  August 12, 2020

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease of immune dysregulation characterized by unchecked inflammatory responses leading to end-organ dysfunction. Primary HLH results from inherited mutations that impair the capacity for immune regulation; secondary HLH arises from the inappropriate response to an immune stimulus, such as infection, malignancy or autoimmunity. What is less well known is…

Filed under:Conditions Tagged with:congenital disorder of glycosylation (CDG)genetic disordershemophagocytic lymphohistiocytosis (HLH)

Case Report: What’s Causing This Severe Case of Rhabdomyolysis?

Aditya S. Pawaskar, MBBS, MD, & Weishali V. Joshi, MD  |  August 12, 2020

Rhabdomyolysis is a clinical syndrome characterized by muscle tissue necrosis and release of intramuscular components into the circulation. Typical manifestations include muscle pain and myoglobinuria, causing dark urine. Serum creatinine kinase (CK) enzyme levels are usually markedly elevated. Severity can range from muscle enzyme elevation in the serum of an otherwise asymptomatic patient to extremely…

Filed under:Conditions Tagged with:hypopituitarismhypothyroidismrhabdomyolysis

  • « Previous Page
  • 1
  • …
  • 93
  • 94
  • 95
  • 96
  • 97
  • …
  • 328
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences